We thank N. McMillan for TC-1 cells, S.M. Jane for HaCaT cells, S. Lakhani for BT-549, MDA-MD-231 and HS-578T cells, J. Hooper for SK-OV-3 cells; S. Chu and F. Sharafath for help with the xCELLigence experiments; The Cancer Therapeutics CRC for the GSK human STING agonist; D. De Nardo for the WEHI-112 TBK1 inhibitor; and Frances Cribbin for editorial assistance; we also acknowledge the Monash Health Translational Precinct Research Platforms for access to the RT-qPCR instruments and cell line sequencing. This evidence concerns the gene STING1 and cancer.